Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Part of paid clinical trials in Fountain Valley, California.

Sponsor
University of California, Los Angeles
Study ID
NCT04354545
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • Xiidra (Lifitegrast ophthalmic solution) 5% — DRUG
    FDA approved lifitegrast opthalmic solution eye drop

Study Details

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Key Dates

Start date
Apr 1, 2021
Status verified
Dec 2025
Primary completion
Dec 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
75 participants (estimated)

Arms

  • Arm: Group 1
    Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks

Primary Outcome Measure

Change from baseline to week 12 in corneal fluorescein staining score [ Time Frame: From baseline to Week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Doheny Eye Center UCLAFountain ValleyCalifornia92708
Benjamin B Bert, MD
[email protected]
7149631444

Find similar trials in Fountain Valley, CA

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Doheny Eye Center UCLA· Fountain Valley, CA

Related Studies